- Home
- CRVS vs ONDS Comparison
CRVS vs ONDS Comparison
Compare CRVS & ONDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- ONDS
- Stock Information
- Founded
- CRVS 2014
- ONDS 2014
- Country
- CRVS United States
- ONDS United States
- Employees
- CRVS N/A
- ONDS N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- ONDS Telecommunications Equipment
- Sector
- CRVS Health Care
- ONDS Telecommunications
- Exchange
- CRVS Nasdaq
- ONDS Nasdaq
- Market Cap
- CRVS 305.4M
- ONDS 326.8M
- IPO Year
- CRVS 2016
- ONDS N/A
- Fundamental
- Price
- CRVS $4.11
- ONDS $2.13
- Analyst Decision
- CRVS Strong Buy
- ONDS Strong Buy
- Analyst Count
- CRVS 4
- ONDS 2
- Target Price
- CRVS $15.00
- ONDS $3.25
- AVG Volume (30 Days)
- CRVS 1.2M
- ONDS 20.8M
- Earning Date
- CRVS 08-05-2025
- ONDS 08-13-2025
- Dividend Yield
- CRVS N/A
- ONDS N/A
- EPS Growth
- CRVS N/A
- ONDS N/A
- EPS
- CRVS N/A
- ONDS N/A
- Revenue
- CRVS N/A
- ONDS $10,815,867.00
- Revenue This Year
- CRVS N/A
- ONDS $243.35
- Revenue Next Year
- CRVS N/A
- ONDS $118.81
- P/E Ratio
- CRVS N/A
- ONDS N/A
- Revenue Growth
- CRVS N/A
- ONDS N/A
- 52 Week Low
- CRVS $1.78
- ONDS $0.54
- 52 Week High
- CRVS $10.00
- ONDS $3.40
- Technical
- Relative Strength Index (RSI)
- CRVS 53.94
- ONDS 60.24
- Support Level
- CRVS $3.79
- ONDS $1.71
- Resistance Level
- CRVS $4.31
- ONDS $1.93
- Average True Range (ATR)
- CRVS 0.29
- ONDS 0.20
- MACD
- CRVS 0.00
- ONDS -0.02
- Stochastic Oscillator
- CRVS 72.64
- ONDS 51.08
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.